Premium
Private equity firm Carlyle has agreed to buy a fifth of Piramal Enterprises Ltd’s pharmaceutical business at some discount but if the drug maker achieves performance milestones even that discount almost evaporates. The discount mentioned above probably springs from the fact that the target firm is private and a sale of shares ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
